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In 1996, oral terbinafine joined itraconazole and fluconazole on the short list of systemic medications that could be used to treat onychomycosis (although fluconazole was not approved for this indication by the US Food and Drug Administration [FDA] , it was commonly used for this purpose). In 1999, ciclopirox was the first topical treatment to be FDA approved. The addition of the topical antifungal agents efinaconazole and tavaborole in 2014 expanded the roster of medications available to more effectively manage onychomycosis in a wide range of patients, including those for whom comorbid conditions, concomitant medications, or patient preference limited the use of systemic antifungals.
tion should be paid to recommendations for baseline and follow-up testing and clinical monitoring.
For example, terbinafine has been associated with hepatic failure, and the prescribing information recommends that liver function tests be performed both at baseline and periodically during treatment. Other adverse events previously reported with the use of terbinafine include taste and smell disturbances that may become permanent, depression, severe neutropenia, and skin diseases such as StevensJohnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), and lupus erythematosus-like illness.
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The prescribing information for itraconazole contains cautions about heart failure, other cardiac effects, including life-threatening arrhythmias, and sudden death (especially when itraconazole is used concomitantly with certain cytochrome P450 inhibitors-see "Drug-Drug Interactions," below). Hearing loss has been reported with the use of this medication, and hepatotoxicity rarely has been reported to occur as early as the first week of treatment. 4 Moreover, in vitro drug resistance has been demonstrated with this and the other azole drug, fluconazole. 4, 7 In addition to in vitro drug resistance, fluconazole use has been associated with hepatotoxicity, significant skin diseases, and prolongation of the QT interval on electrocardiogram. Fluconazole also has been associated with congenital defects, and its use should be avoided during the first trimester of pregnancy. A number of drug-drug interactions-many of which are theoretical-are listed for each of the systemic antifungal medications ( Table 2 ). The prescribing information for each of these medications should be consulted before choosing an oral antifungal. A detailed description of the mechanisms by which these interactions may occur is beyond the scope of this article, so one or two illustrative examples have been chosen for terbinafine, itraconazole, and fluconazole.
Terbinafine, which is metabolized by the cytochrome p450 (CYP450) enzyme 2D6 (CYP2D6), may interact in particular with drugs that are also metabolized by CYP2D6.
1 Although the class of beta-blockers is listed in the prescribing information, not all betablockers may interact to the same degree. Metoprolol-the most commonly prescribed beta-blocking agent in the United States-is the most likely drug in this class to interact with terbinafine. Terbinafine may inhibit the metabolism of metoprolol, resulting in excess systemic levels of metoprolol and a risk for bradycardia, low blood pressure, and, possibly, cardiogenic shock. 8 Itraconazole is metabolized by the CYP3A4 enzyme, a characteristic it shares with several other medications. 4 One interaction of note is itraconazole's inhibition of metabolism of statin drugs, particularly simvastatin and lovastatin; this action can result in rhabdomyolysis. In addition, a potentially fatal interaction can occur when itraconazole is given concomitantly with opioids, particularly methadone; the combination is associated with a high likelihood of a fatal arrhythmia. 9 Fluconazole has been widely studied and demonstrated to be effective against onychomycosis, and, although it is not FDA approved for this indication, it is widely used for treating this infection. Potential interactions include antiarrhythmic drugs, antipsychotics, and antihistamines 7 (although the most problematic among these, terfenadine, is no longer marketed).
However, not on the list derived from the fluconazole prescribing information is an interaction that has been demonstrated recently with tofacitinib-a medication currently approved for rheumatoid arthritis, well studied and likely to be approved for psoriasis and psoriatic arthritis, and being used investigationally in alopecia areata. Fluconazole inhibits tofacitinib's metabolism and, n therefore, may lead to gastrointestinal disturbances, such as severe diarrhea. Furthermore, inhibition of tofacitinib's metabolism may potentiate tofacitinib-related infections, particularly pharyngitis, sinusitis, and bacterial infections; some of these infections may be severe.
10
Topical Agents: Efficacy and Safety Currently, three topical agents are approved for the treatment of onychomycosis: ciclopirox 8% solution, efinaconazole 10%, and tavaborole 10%. No systemic adverse events have been reported with these topical agents, and the incidence of serious local reactions generally is quite low. Because the pivotal studies of these agents were not conducted using standardized protocols, each medication must be considered on its own merits in determining which topical agent to choose for an individual patient. The efficacy rates from the pivotal trials of these three agents are listed in Table 3 .
Ciclopirox
Ciclopirox has antifungal, antibacterial, and anti-inflammatory effects. The phase III pivotal trial protocol included patients between the ages of 18 and 70, with distal subungual onychomycosis of at least one great toenail (target nail) and positive KOH examination and culture for dermatophytic onychomycosis. Involvement of the target nail was no less than 20% and no greater than 65%. The lacquer was painted once daily on the entire nail plate of the target nail(s), along with approximately 5 mm of adjacent skin, the hyponychium, and the accessible ventral surface of the nail plate. The lacquer was removed once weekly with an alcohol wipe. In addition, subjects were required to report each month for professional trimming and debridement of the nails. 11 The guidelines for use specified in the prescribing information for ciclopirox include weekly removal of the lacquer and regular visits to a health care professional for debridement.
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In the two phase III pivotal trials, the complete cure rates reported were 5.5% and 8.5%.

Efinaconazole
Efinaconazole is an azole drug with good potency against T. rubrum, T. mentagrophytes, and C. albicans. The formulation has a low surface tension, causing a "wicking" action that draws the medication around the nail. Studies of in vivo penetration showed that daily application of 10% and 5% solutions to all 10 toenails for 28 days demonstrated high levels of nail deposition and low systemic exposure to efinaconazole and its metabolite. 13 In two parallel, 52-week, phase III, multicenter trials of efinaconazole, 14 a total of 1,655 subjects were randomized, in a 3:1 ratio, to receive either efinaconazole or placebo. Included were subjects between 18 and 70 years of age with mild to moderate onychomycosis affecting 20% to 50% of at least one great toenail, with at least 3 mm of uninfected nail as measured from the proximal nail fold, and a nail plate thickness no greater than 3 mm. Nail trimming, to any extent, was permitted but not required.
The cure rates in the efinaconazole pivotal trials were 15% and 18%.
14,15
Tavaborole
Tavaborole represents a new class of antifungal agent, a boronbased therapy. Boron is a low-molecular-weight, highly reactive molecule that targets protein synthesis. 16 In preclinical studies, tavaborole demonstrated excellent and rapid penetration through the nail plate and into the nail bed. 17 The inclusion criteria for the two parallel, phase III pivotal trials of tavaborole had several of the same or similar inclusion criteria as the pivotal trials of the other two topical antifungals: laboratory-confirmed onychomycosis of at least one great toenail; nail involvement of between 20% and 60%; at least 3 mm of uninvolved nail, as measured from the proximal nail fold; and nail thickness of 3 mm or less. 18 However, these tavaborole studies differed from the ciclopirox n Regimens: All of these medications are approved for daily application for 48 weeks.
*Results of two phase III trials, respectively.
and efinaconazole trials in three important respects, which should be considered when comparing cure rates. First, in the tavaborole studies, no upper age limit was established (whereas the upper age limit in the other two studies was 70). Second, in the tavaborole studies, the medication was to be applied without debridement. Third, the final nail trimming prior to the final assessment allowed no less than 1 mm of growth at the distal edge of the target nail(s); in the other studies, the nail could be trimmed to the distal edge of the nail, which could affect the grading results. The complete cure rates in the tavaborole pivotal trials were 9.5% and 6.5%. 16, 18 Mechanisms of Action The antifungal activities of the medications used to treat onychomycosis vary by class (Figure) . The systemic agents itraconazole and fluconazole and the topical agent efinaconazole are in the azole class-specifically, in the triazole category. Triazoles work by inhibiting 14α-demethylase of the P450 enzyme, blocking conversion of lanosterol to ergosterol in fungal cells; ergosterol is essential to fungal cell growth. 4, 7, 15 Terbinafine, in the allylamine class, also inhibits ergosterol biosynthesis, but at a different point in the pathway. Rather than affecting P450 and lanosterol-converting enzymes, the allylamines inhibit squalene oxidase, resulting in lethal fungal cell membrane changes.
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Ciclopirox is a synthetic antifungal agent. Its mechanism of action has not been clearly established but seems to involve both the inhibition of the metal-dependent enzymes responsible for the degradation of peroxides within the fungal cell as well as upregulation of fungicidal reactive oxygen formation within the fungal cytoplasm. 19, 20 Tavaborole's mechanism of action also is not completely understood, but it is thought to most likely involve inhibition of the enzyme leucine aminoacyl-transfer ribonucleic acid synthetase. Tavaborole is active against most strains of T. rubrum and T. mentagrophytes, the two species most commonly found in onychomycosis. No resistance to tavaborole has been observed. 16 Efinaconazole shows in vitro activity against T. rubrum and T. mentagrophytes. No clinically significant evidence of drug resistance to efinaconazole has been reported.
Conclusion
In the pivotal trials for antifungal therapy for onychomycosis, the FDA-mandated criterion for efficacy is "complete cure." This is defined as negative results on both direct microscopic examination of samples prepared with 10% to 20% KOH and on mycologic culture, plus a substantially clinically improved nail (although not necessarily 100% normal appearance). In contrast, what might be called "effective treatment" is marked by a negative culture (regardless of the result of microscopic KOH examination, as a falsepositive test may occur when nonviable hyphae are present), and substantial clinical improvement in the appearance of the nail. In some patients, particularly those with early disease and little or no nail discoloration or deformity, a complete cure may be a realistic expectation. In those with infection of longer duration and a moderate degree of discoloration and deformity, a good resultie, a clinical cure-is resolution of the infection, documented on direct microscopy and culture, and an appreciable improvement in the appearance of the nail. Effective treatment should be the baseline goal for the majority of patients. Resolution of infection, documented by a negative culture, and substantial improvement in nail appearance are achievable benchmarks in most cases, assuming that the medication chosen is effective against the infecting organism(s) and that the patient uses the treatment as prescribed.
